spacer
home > ebr > Winter 2022
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2022

   
Text
PDF
bullet
DEVELOPMENT AND PRODUCTION
Development and Production

Understanding the Bottlenecks Holding Back Biologics

What are the recent developments in biologics production, how have these developments been impacted by COVID-19, and what does the future hold for the sector?

Alex Page at Watson-Marlow
 
view
download pdf
bullet
rare diseases
Rare Diseases

Pooling Efforts to Drive Gene Therapies for Rare Diseases

A three-pronged approach that will drive gene therapies to market in a more efficient and financially viable way, and then ultimately into the hands of patients. This requires improved collaboration across the biopharma industry.

Christian Schneider at Biopharma Excellence
 
view
download pdf
bullet
Antimicrobial resistance
Antimicrobial Resistance

The Balancing Act of Antimicrobial Technologies

The COVID-19 pandemic has led to a boom in antimicrobial products, bringing with it its own risks. With antimicrobial resistance a growing concern, navigating the future will be a complex task.

India Toomey and Nadia Tsao at IDTechEx
 
view
bullet
Cell and Gene Therapy
Cell and Gene Treatments

Beyond CAR T Cells: The Future of Adoptive Cell Therapies

Looking ahead towards the promising future of adoptive cell therapies, and identifying the challenges that lie in the way of them becoming the go-to treatment for cancer patients.

Marwan Alsarraj at Bio-Rad
 
view
download pdf
Cell and Gene Therapy

Increasing the Accessibility of Life-Changing Treatments

The emergence and growth of cell and gene therapies means a potentially game-changing treatment for patients with a range of cancers and rare diseases. How can researchers in this area begin to overcome challenges and help them become a more affordable and accessible option?

Hilary Thomas, Anu Solanki, and Luca Pinton at PA Consulting.
 
view
download pdf
Cell and Gene Treatments

Overcoming the Challenges of Large-Scale Plasmid

Production What are the difficulties faced when dealing with plasm production, and how will WuXi’s recent acquisition of OXGENE streamline the process of getting important therapies to market?


 
view
download pdf
Cell and Gene Treatments

Modelling Genetic Disease: iPS Cell Line Development Using Gene Editing

Deriving patient-specific cell lines that can be used to generate functional tissue for disease modelling, drug discovery, and screening is a worthwhile endeavour – and the right tools and strategies can minimise the required time and effort.

Amanda Haupt at Horizon Discovery, a PerkinElmer Company
 
view
download pdf
bullet
Cell Culture
Cell Culture

Exploring CO2 Incubator Technologies Designed for Cleanroom Cell Culturing

The laboratory manufacturers who are turning towards dedicated CO2 incubators in order to effectively cultivate novel cell-based therapies.
 
view
download pdf
Cell Culture

A Pressing Need for Accurate Preclinical Models of Metabolic Disease

The technology that is revolutionising the way that we understand, and develop targeted biotherapeutics for, the modern epidemic of metabolic disease.

Dr Anthony Berger at CN Bio
 
view
download pdf
bullet
Biomarkers
Biomarkers

Dynamising Biomarker R&D with Smarter Biospecimens

In the midst of turmoil caused by the COVID-19 pandemic, what are the obstacles facing scientists looking to work with biospecimens and how can they be overcome?

Zara Puckrin, David Bunton, Graeme Macluskie, and Rachna Goyal at REPROCELL
 
view
download pdf

Infectious Diseases
Infectious Diseases

Finding the Signal Among the Noise – The Challenges of Flavivirus Serology

Despite flaviviruses representing a growing global health concern, means of diagnosis continue to suffer from low specificity and breadth – but what recent efforts have been made to improve them and what does the future hold for this vital research?

James Shore at The Native Antigen Company
 
view
download pdf
Infectious Diseases

The Future of Vaccines for Infectious Diseases

How we can make better use of the often-overlooked power of cytotoxic T cells using arenaviruses in the development of vaccines for infectious diseases.

Klaus Orlinger, Henning Lauterbach, Daniel Pinschewer, and Igor Matushansky at HOOKIPA Pharma
 
view
download pdf
Infectious Diseases

Diagnosing Emerging Variants of SARSCoV- 2 for Effective Transmission Control

With the Omicron variant increasing the spread of COVID-19 – just like the Delta variant before it – testing methods are in a constant race to keep up with the virus and its mutations.

David Wilson at Avacta
 
view
download pdf
Infectious Diseases

A New Generation of Agents Combatting Antibiotic Resistance

The strain being put on the healthcare system by the increasing use of antibiotics in both medicine and agriculture has led to more innovative solutions to combat antibioticresistant bacteria.

Dr Heather Fairhead at Phico Therapeutics
 
view
download pdf
Infectious Diseases

Bioelectronic Assay Identifies Potential COVID-19 Therapeutic Targets

It is essential that safe and effective treatments be found for COVID-19 as the world comes to terms with the long-term presence of the virus – and bioelectronic assays will be key moving forwards.

Jim Ross at Axion Biosystems
 
view
download pdf
bullet
AI in Drug Discovery
AI in Drug Discovery

The Rise of Machine Learning and What it Means For Biological and Chemical Data

Despite advances, there is still one bottleneck holding back more significant developments in drug discovery. What are the problems, and how should they be addressed?

Nil Adell-Mill at Arctoris
 
view
download pdf
AI in Drug Discovery

Phenomics: What It Is and Why It Is the Future of Drug Discovery

The future of drug discovery has increasingly been pointing away from the tried-and-tested method of target-based screening and towards a more accurate and effective technique.

Stacie Calad-Thomson at BioSymetrics
 
view
download pdf
AI in Drug Discovery

AI Does Not Drive Novel Drug Discovery, Science Does

The pharma industry is being touted as the next big beneficiary of the game-changing effects of AI. But where does it fit in within the overall process of drug discovery?

Andrew Radin at Aria Pharmaceuticals
 
view
download pdf
bullet
Academia in Pharma
Academia and Pharma

Unravelling New Disease Biology at the Interface Between Academia and the Pharma Industry

Drug development is a lucrative business, but breakthrough innovations are just as important for healthcare. How can different perspectives lead to key advances in research and development?

Christian Tidona at BioMed X Institute
 
view
download pdf
bullet
Biomaterials
Biomaterials

Biomaterials: Challenges, Characteristics, and Considerations

The diverse range of uses of biomaterials, and the difficulties, challenges and considerations that play a part in their clinical development.

Dr Jeff Daelman at Rousselot
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Scitara and Veeva Partner to Help Companies Optimize QC Lab Productivity


More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement